Key Points
- COO Kathleen Goin sold 4,302 shares of Palvella at an average price of $86.23 for a total of about $370,961, a transaction disclosed in an SEC filing.
- The stock traded up 2.8% to $94.09 on higher-than-average volume; analysts are largely positive with an average consensus target of $111.92 and several recent price-target raises.
- Palvella is a clinical-stage biopharma focused on rare genetic skin diseases and recently missed quarterly EPS estimates (reported $(1.03) vs. $(0.85) expected), with analysts projecting a -3.69 EPS for the year.
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,302 shares of the company's stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $86.23, for a total transaction of $370,961.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Palvella Therapeutics Trading Up 2.8%
Shares of NASDAQ PVLA traded up $2.55 during mid-day trading on Friday, reaching $94.09. The company had a trading volume of 232,882 shares, compared to its average volume of 122,671. The firm has a 50 day simple moving average of $72.01 and a two-hundred day simple moving average of $46.93. Palvella Therapeutics, Inc. has a 52-week low of $11.17 and a 52-week high of $101.94. The stock has a market cap of $1.11 billion, a P/E ratio of -35.78 and a beta of -0.05.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18). On average, equities analysts expect that Palvella Therapeutics, Inc. will post -3.69 EPS for the current year.
Analyst Ratings Changes
A number of analysts recently issued reports on the company. Lifesci Capital began coverage on Palvella Therapeutics in a research report on Monday, August 4th. They issued an "outperform" rating and a $90.00 target price for the company. TD Cowen boosted their price objective on Palvella Therapeutics from $65.00 to $97.00 and gave the company a "buy" rating in a research note on Thursday, November 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Palvella Therapeutics in a report on Wednesday, October 8th. Raymond James Financial upgraded shares of Palvella Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their target price for the stock from $92.00 to $143.00 in a research report on Wednesday. Finally, Canaccord Genuity Group upped their price target on shares of Palvella Therapeutics from $90.00 to $148.00 and gave the company a "buy" rating in a research report on Thursday, November 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $111.92.
Check Out Our Latest Stock Report on Palvella Therapeutics
Institutional Trading of Palvella Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Archer Investment Corp purchased a new position in shares of Palvella Therapeutics in the 3rd quarter valued at approximately $28,000. Russell Investments Group Ltd. purchased a new stake in shares of Palvella Therapeutics during the third quarter worth approximately $36,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Palvella Therapeutics during the second quarter worth $37,000. AlphaQuest LLC purchased a new position in Palvella Therapeutics in the 3rd quarter valued at $164,000. Finally, JPMorgan Chase & Co. grew its position in Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock valued at $73,000 after buying an additional 3,242 shares during the last quarter. 40.11% of the stock is owned by hedge funds and other institutional investors.
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
